Alniditan

Drug Profile

Alniditan

Alternative Names: R-91274

Latest Information Update: 08 Jul 1997

Price : $50

At a glance

  • Originator Janssen L.P.
  • Class Antimigraines; Benzopyrans
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 08 Jul 1997 Discontinued-III for Migraine in Belgium (SC)
  • 17 Jun 1997 Phase-III clinical trials for Migraine in Belgium (SC)
  • 11 Jun 1996 A clinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top